Zealand Pharma's petrelintide drops the GLP-1 component entirely and still produced 10.7% weight loss with placebo-like tolerability in its lead Phase 2 trial — a real test of whether amylin alone can compete with the incretin class, backed by a $5.3 billion Roche partnership.
Petrelintide
-
Petrelintide and the Amylin-Only Bet